Perrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

Rhea-AI Summary

Perrigo (NYSE: PRGO) said it will release fourth quarter and fiscal year 2025 results on February 26, 2026 and host an earnings call at 8:30 A.M. ET. The call will be live via webcast and available by phone; a taped replay is provided through March 5, 2026.

Perrigo is a consumer health company with leading OTC brands and directs investors to its SEC filings for risks and additional details.

Key Figures

Earnings release date: February 26, 2026 Conference call time: 8:30 A.M. (EST) US dial-in number: 800-836-8184 +5 more

8 metrics

Earnings release date February 26, 2026 Planned Q4 and FY 2025 results release

Conference call time 8:30 A.M. (EST) Start time for earnings conference call

US dial-in number 800-836-8184 Domestic access for live earnings call

International dial-in number 646-357-8785 International access for live earnings call

Call reference ID 52719 Reference ID for live call access

Replay start time 12:00 P.M. (EST) February 26, 2026 Approximate start of taped replay availability

Replay end date March 5, 2026 Replay available until midnight

Replay access code 52719# Access code for replay lines

Market Reality Check

Price: $14.38 Vol: Volume 2,044,627 is sligh...

normal vol

$14.38 Last Close

Volume Volume 2,044,627 is slightly below the 20-day average of 2,233,994, suggesting no abnormal trading ahead of the earnings date announcement. normal

Technical Shares at $14.38 are below the 200-day MA of $20.97 and well below the 52-week high of $30.93, hovering closer to the 52-week low of $12.17.

Peers on Argus

PRGO was down 1.51% while peers were mixed: PBH up 1.21%, AMRX, INDV, BHC and HC...

PRGO was down 1.51% while peers were mixed: PBH up 1.21%, AMRX, INDV, BHC and HCM down between about 1–4%. With no momentum-screener flags and mixed peer moves, trading appeared more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Nov 05 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 05	Q3 2025 earnings	Negative	-25.2%	Q3 2025 sales decline, flat EPS, and lowered full-year outlook.
Nov 05	Strategic review	Negative	-25.2%	Strategic review of infant formula business and prior $240M investment.
Nov 04	Investor conference	Neutral	-1.7%	Participation in Jefferies Miami Consumer Conference investor meetings.
Oct 29	Dividend declaration	Positive	-1.5%	Announcement of $0.290 per share quarterly dividend and key dates.
Oct 22	Earnings date set	Neutral	-1.3%	Notification of Q3 2025 earnings release and call logistics.

Pattern Detected

Operational and strategic updates, especially the November 2025 earnings and infant formula review, coincided with a sharp sell-off, while even a dividend declaration saw a modest negative price reaction.

Recent Company History

Over the past few months, Perrigo’s news flow has centered on earnings, portfolio strategy, and shareholder returns. On Nov 5, 2025, Q3 2025 results and an infant formula strategic review preceded a ~25% drop, highlighting sensitivity to guidance and portfolio moves. A quarterly dividend of $0.290 per share on Oct 29, 2025 still saw a small decline. The prior Q3 earnings-date announcement on Oct 22, 2025 had only a mild negative reaction. Today’s FY 2025 earnings date fits this pattern of scheduled communications.

Market Pulse Summary

This announcement sets the timetable for Perrigo’s Q4 and full-year 2025 update on February 26, 2026...

Analysis

This announcement sets the timetable for Perrigo’s Q4 and full-year 2025 update on February 26, 2026, giving investors a clear focal point after a volatile 2025 marked by a sharp reaction to Q3 results and an infant formula strategic review. With shares trading below the 200-day MA and nearer the 52-week low than the high, upcoming disclosures on sales trends, profitability, and portfolio changes will be key metrics to watch on the call.

Key Terms

over-the-counter (otc), forward-looking statements, form 10-k

3 terms

over-the-counter (otc) medical

"As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers..."

Over-the-counter (OTC) describes stocks and other securities traded directly between buyers and sellers outside formal exchanges, using brokers, dealers, or electronic networks. For investors it matters because OTC trading often means lower transparency, fewer rules and thinner trading volume—like buying at a small flea market instead of a big supermarket—so prices can swing more and the risk of not being able to sell quickly is higher.

forward-looking statements regulatory

"This press release includes, and the matters discussed... will include certain "forward-looking statements"..."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

form 10-k regulatory

"...including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2024."

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

AI-generated analysis. Not financial advice.

DUBLIN, Feb. 13, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that it plans to issue its fourth quarter and fiscal year 2025 financial results on Thursday, February 26^th, 2026, and host a conference call beginning at 8:30 A.M. (EST).

The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 52719. A taped replay of the call will be available beginning at approximately 12:00 P.M. (EST) Thursday, February 26, until midnight Thursday, March 5, 2026. To listen to the replay, dial 888-660-6345, International 646-517-4150, and use access code 52719#.

About Perrigo

Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.

Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill^®, Mederma^®, Compeed^®, EllaOne^®, and Jungle Formula^®.

For more information, visit www.perrigo.com.

Forward-Looking Statements 

This press release includes, and the matters discussed in Perrigo's upcoming earnings release will include certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors—many of which are beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2024.

Perrigo Contact

Bradley Joseph, Vice President, Global Investor Relations, (269) 686-3373, E-mail: bradley.joseph@perrigo.com

Nicholas Gallagher, Associate Director, Global Investor Relations, (269) 686-3238, E-mail: nicholas.gallagher@perrigo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-to-release-fourth-quarter-and-fiscal-year-2025-financial-results-on-february-26-2026-302687665.html

SOURCE Perrigo Company plc

FAQ

When will Perrigo (PRGO) release Q4 and fiscal year 2025 financial results?

Perrigo will release its Q4 and fiscal year 2025 financial results on February 26, 2026. According to the company, the announcement will be followed by a conference call beginning at 8:30 A.M. ET and a webcast for investors and analysts.

How can investors join the Perrigo (PRGO) earnings conference call on February 26, 2026?

Investors can join the Perrigo earnings call via live webcast or by phone with the provided dial-in numbers and reference ID. According to the company, the webcast will be available in the investor relations section of Perrigo's website.

When and how can I listen to the Perrigo (PRGO) taped replay of the February 26, 2026 call?

A taped replay will be available beginning about 12:00 P.M. ET on February 26 through midnight March 5, 2026. According to the company, investors can access the replay by phone using the listed access code and international numbers.

What will Perrigo (PRGO) include in the February 26, 2026 earnings release and call?

The earnings release and call will present fourth quarter and full-year 2025 financial results and discussion of performance. According to the company, materials will include forward-looking statements and direct investors to SEC filings for detailed risk disclosures.

Where can I find Perrigo (PRGO) investor materials and SEC filings referenced for the February 26, 2026 results?

Investor materials and SEC filings are available on Perrigo's investor website and SEC filings portal. According to the company, its investor relations site hosts the webcast, press release, and links to Form 10-K and other SEC filings for deeper detail.